Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

ory to, or who have progressed within six months of completing, treatment with first-line platinum chemotherapy (cisplatin or carboplatin), is being conducted at clinical sites in Europe and India.

"Since the initiation of the SPEAR trial in the second quarter of 2007, we have made significant progress in opening approximately 100 clinical sites and in treating patients," said David A. Karlin, M.D., senior vice president, clinical development and regulatory affairs for Poniard. "We anticipate reaching our enrollment target in the first half of 2008, potentially supporting a New Drug Application filing in 2009."

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the FDA in November 2005 for picoplatin for the treatment of SCLC.

In addition to the ongoing SPEAR trial, Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer.

About Small Cell Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, bu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  Diplomat, the nation,s largest independent specialty pharmacy, has ... the Board of Directors on September 15, 2014. Mr. ... as chair of the Audit Committee. ... compliance and operating experience in the health care field.  ... financial officer, chief operating officer and secretary of Patient ...
(Date:9/19/2014)... , Sept. 19, 2014  Alere Inc. (NYSE: ... diagnostics, issued the following statement today in support of ... Bacteria. "As the global leader in rapid ... establishing a national strategy to address the serious threat ... work with the Administration on initiatives to promote the ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today that ... notes. The Company intends to use the ... of the outstanding borrowings under its credit facility and for ... Smith Incorporated, BNP Paribas Securities Corp. and RBS Securities Inc. ...
... 7, 2011 Vermillion, Inc. (NASDAQ: ... to present at the Stephens Fall Investment Conference. The conference ... New York City on November 15-16, 2011. Vermillion,s ... Wednesday, November 16, 2011 at 10:30 a.m. Eastern time, with ...
Cached Medicine Technology:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011 2
(Date:9/21/2014)... 21, 2014 The Laboratory Testing Services ... manufacturers perform tests on items ranging from consumer and ... society, pressure on operators to ensure the safety and ... greater number of government safety regulations and consumer lawsuits ... to sale. Although revenue briefly dipped in 2009 as ...
(Date:9/21/2014)... "I wanted to be able to ... sugary, foul-tasting energy drinks," said an inventor from Fresh ... to drink plain, old coffee. That is why I ... developed ENERG CHEWING GUM to provide a healthy energy ... formula contains nutritious vitamins, minerals and antioxidants. It also ...
(Date:9/21/2014)... 21, 2014 The Illinois Joining ... host a statewide symposium ( tinyurl.com/ILBHC14 ) focused ... their Families. Sponsored by the VNA Foundation, Thresholds, ... Grant, and Health & Disability Advocates, the symposium ... Hilton Hotel in Springfield, IL. The symposium ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 The ... implements and supports electronic medical records (EMR) and ... from federal healthcare legislation during the past five ... so during the five years to 2019. The ... Health Act established Medicare and Medicaid incentives to ...
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
Breaking Medicine News(10 mins):Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Laboratory Testing Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 2Health News:Enhancing Clinical Competence to Serve Veterans, a Statewide Symposium 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2
... million, Five-year Grant, from New York State Department of,Health, ... Lead,Poisoned, NEW YORK, Feb. 11 The Lead ... Montefiore,(CHAM) has been named one of three State Regional ... healthcare delivery for children and,pregnant women with elevated blood ...
... Part of MedCath,s Growth Plans, CHARLOTTE, N.C., Feb. ... physician partners today announced plans to double,the number of ... a 120-bed acute care and heart hospital., The ... into 60 inpatient beds, which will be used to ...
... from the UC Davis M.I.N.D. Institute shows that an ... be linked with the repetitive behavior also called ... studies are needed to confirm the outcome, this result ... prenatal period could be a causal factor for the ...
... SOUTH SAN FRANCISCO, Calif., Feb. 11 ... SpA have announced an agreement granting,an exclusive ... distribution of,Anesiva,s Zingo(TM) (lidocaine hydrochloride monohydrate) powder,intradermal ... France,Germany, Netherlands, Belgium and Luxembourg. Under the ...
... Unlike other epilepsy meds, Trileptal was no better than ... -- The epilepsy drug oxcarbazepine (Trileptal) does not seem ... finds. , Migraines affect more than 28 million Americans, ... effective in preventing these severe headaches. For this reason, ...
... American Academy of ... Dermatology, ... that validates the benefits of alpha-hydroxy acid (AHA),at- home peels in ... as lasers and microdermabrasion. The,data were highlighted in the Poster Session ...
Cached Medicine News:Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 2Health News:Prenatal exposure to maternal antibodies linked to autistic behaviors in offspring 3Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 2Health News:Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries 3Health News:Epilepsy Drug Doesn't Prevent Migraines 2Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2
Comes complete with its own case. A unique integrated design with no need for two separate bars., ,Optical surfaces are recessed for optimum protection. Extensive prism power 1,2,3,4,6,8,10,15,20...
Well established test for children but suitable for disabled people, those with learning difficulties or patients who do not share a common language with the examiner....
... Carotid Stent System is designed to provide easy ... carotid atherosclerosis and are at high risk for ... RX ACCULINK Carotid Stent System is 6F sheath/8F ... The RX ACCULINK utilizes rapid exchange (RX) technology ...
The New Vantage Plus. The PLUS gives you: ,P Premium intelligent optics ,L Lighter weight and brighter images ,U Unique wireless patented technology ,S Smaller and more compact size ...
Medicine Products: